← All indications
Immune System Diseases
Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.
Subtype terms (11)
More specific conditions that are subtypes of Immune System Diseases in the MeSH hierarchy.
- Autoimmune Diseases
213 drugs (119 approved, 94 experimental)
- Erythroblastosis, Fetal
4 drugs (3 approved, 1 experimental)
- Glomerulonephritis, Membranoproliferative
16 drugs (10 approved, 6 experimental)
- Graft vs Host Disease
291 drugs (160 approved, 131 experimental)
- Hypersensitivity
213 drugs (105 approved, 108 experimental)
- Immune Reconstitution Inflammatory Syndrome
7 drugs approved
- Immunologic Deficiency Syndromes
23 drugs (20 approved, 3 experimental)
- Immunoproliferative Disorders
20 drugs (10 approved, 10 experimental)
- Mast Cell Activation Disorders
3 drugs experimental
- Purpura, Thrombocytopenic
10 drugs (9 approved, 1 experimental)
- Transfusion Reaction
11 drugs (7 approved, 4 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (28)
- ibuprofen
- etanercept
- tacrolimus
- ginseng
- mesalamine
- adalimumab
- pneumococcal 13-valent conjugate vaccine
- acetaminophen
- immune globulin (human)
- rocuronium
- levobupivacaine
- mycophenolate
- hepatitis a vaccine, inactivated
- inactivated japanese encephalitis vaccine
- inactivated influenza vaccine
- infliximab
- fentanyl
- tick-borne encephalitis vaccine
- azithromycin
- midazolam
- measles, mumps, and rubella vaccine
- oxygen
- morphine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- ada-transduced cd34+ cells
- meningococcal (group B) vaccine
- mrna-1273
Phase 3 trials (23)
- vitamin d3
- abetimus
- busulfan
- cirmtuzumab
- dupilumab
- RSVPreF3
- histamine
- famotidine
- bovine colostrum
- ibrutinib
- pf-04965842
- stem cells
- pentoxifylline
- allogeneic adipose derived mesenchymal stem cell
- bifidobacterium longum
- phenol
- mycobacterium w vaccine
- fludarabine
- thiotepa
- lactobacillus casei
- efgartigimod
- pegcetacoplan
- rhgad65
Phase 2 trials (78)
- montelukast
- methylprednisolone
- benralizumab
- diphenhydramine
- tofacitinib
- denileukin diftitox
- doxycycline
- prednisone
- gemcitabine
- l-glutamine
- naltrexone
- lymphocyte immune globulin, anti-thymocyte globulin (equine)
- albumin (Human)
- hydroxyurea
- nivolumab
- inulin
- pembrolizumab
- l-alanine
- levamisole
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- niacin
- pamidronate
- pentostatin
- sparsentan
- qbkpn
- allogeneic hematopoietic stem cells
- ruxolitinib
- Isatuximab
- sirolimus
- arsenic trioxide
- +48 more
Phase 1 trials (39)
- allogeneic natural killer cells
- anti-mycoplasma hominis antibodies
- bay1834845
- bendamustine
- deferoxamine
- hemopoietic stem cell
- aldesleukin
- Sovleplenib
- ic9-car19 cells
- omalizumab
- ocrelizumab
- palbociclib
- cyclosporine
- 6-prenylnaringenin
- 8-prenyl-naringenin
- allogeneic cord blood
- dapirolizumab pegol
- fetal mesenchymal stem cells
- glucagon-like peptide-1
- ky1005
- walnut
- rivaroxaban
- albuterol
- silymarin
- sargramostim
- zinc
- bay1830839
- cd138 car-t cells
- tolerogenic dendritic cells
- bcma/cd19 dual-target car-t
- +9 more
Other trials (68)
- metformin
- maltodextrin
- 23-valent pneumococcal polysaccharide vaccine
- norgestrel
- secukinumab
- aloe vera
- acetylcysteine
- astaxanthin
- bifidobacterium animalis
- bovine lactoferrin
- clofarabine
- cranberry
- echinacea
- efalizumab
- cannabidiol
- palmitoylethanolamide
- somatropin
- belumosudil
- lipid emulsion
- desogestrel
- cow milk
- pegvisomant
- polysulfone
- hepatitis b vaccine (recombinant)
- lactoferrin
- house dust mite allergen
- tocilizumab
- estradiol
- alemtuzumab
- glucose
- +38 more
Organizations
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (12)
- Regeneron
- Pfizer
- Sanofi
- Inmunotek S.L.
- La Jolla Pharmaceutical Company
- Center for International Blood and Marrow Transplant Research
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Federal University of Bahia
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
- Medical College of Wisconsin
- University of Minnesota
Organization Involved with Phase 2 Indications (31)
- Celgene
- Amgen
- AstraZeneca
- Diamyd
- Immune Design
- Juno Therapeutics, Inc.
- Lung Biotechnology PBC
- Medsenic
- Stem Cells Arabia
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Aarhus University
- Indiana University
- McMaster University
- University of Leicester
- University of Athens
- University of Bordeaux
- Fudan University
- Pavlov First Saint Petersburg State Medical University
- University of Limoges
- University of Toulouse
- Hellenic Institute for the Study of Sepsis
- Zhongsh Ophthalmic Center
- Sun Yat-Sen University
- University of North Carolina at Chapel Hill
- Linkoping University
- Washington University in St. Louis
- Blood and Marrow Transplant Clinical Trials Network
- Fovea Pharmaceuticals
- Chinese Academy of Medical Sciences
- Celularity, Inc.
- +1 more
Organization Involved with Phase 1 Indications (13)
- Biogen
- Bellicum Pharmaceuticals
- Kymab Limited
- Shanghai Henlius Biotech
- Celal Bayar University
- Ege University
- University of Washington
- Hoosier Cancer Research Network
- Russian Academy of Medical Sciences
- Stanford University
- Hammersmith Medicines Research
- The Scientific and Technological Research Council of Turkey
- V Foundation
Organization Involved with Other Experimental Indications (12)
- Laboratoire français de Fractionnement et de Biotechnologies
- Green Beat
- Medical University of Graz
- Stanley Medical Research Institute
- Thomas Jefferson University
- University of New Mexico
- University of Cambridge
- University of Lille
- University of Oxford
- McPin Foundation
- University of Helsinki
- Nemours Children's Health System